ForwardVue Pharma

Forward Vue Pharma

Biotechnology, 17 E MDW Ln, Cambridge, Massachusetts, 01949, United States, 1-10 Employees

forwardvuepharma.com

  • LinkedIn

phone no Phone Number: +12*********

Who is FORWARDVUE PHARMA

ForwardVue Pharma is an emerging biopharmaceutical company developing a small synthetic compound caroboxyamidotriazole, that acts via the novel mechanism of ORAI-1 inhibition and can be f...

Read More

map
  • 17 E MDW Ln, Cambridge, Massachusetts, 01949, United States Headquarters: 17 E MDW Ln, Cambridge, Massachusetts, 01949, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 8042 | NAICS Code: 621320 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from FORWARDVUE PHARMA

ForwardVue Pharma Org Chart and Mapping

Employees
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding ForwardVue Pharma

Answer: ForwardVue Pharma's headquarters are located at 17 E MDW Ln, Cambridge, Massachusetts, 01949, United States

Answer: ForwardVue Pharma's phone number is +12*********

Answer: ForwardVue Pharma's official website is https://forwardvuepharma.com

Answer: ForwardVue Pharma's revenue is Under $1 Million

Answer: ForwardVue Pharma's SIC: 8042

Answer: ForwardVue Pharma's NAICS: 621320

Answer: ForwardVue Pharma has 1-10 employees

Answer: ForwardVue Pharma is in Biotechnology

Answer: ForwardVue Pharma contact info: Phone number: +12********* Website: https://forwardvuepharma.com

Answer: ForwardVue Pharma is an emerging biopharmaceutical company developing a small synthetic compound caroboxyamidotriazole, that acts via the novel mechanism of ORAI-1 inhibition and can be formulated to deliver potent anti-angiogenic effects for 6-12 months. Carboxyamidotriazole has been administered to over 900 patients systemically to treat advanced cancer thereby allowing more rapid progress to Phase 2 once IND enabling ocular toxicity is completed. ForwardVue Pharma has secured initial seed round funding in order to advance pre-clinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access